RevBio Issued 10th U.S. Patent for Tetranite Regenerative Bone Adhesive

RevBio was recently issued a patent entitled “Compositions and Methods for Adhesion to Surfaces,” which is the tenth U.S. patent covering the company’s Tetranite bone adhesive technology.

The patent expands the protected technology to include injectable mineral-organic structural bone adhesive compositions that comprise alpha tricalcium phosphate. It complements RevBio’s existing U.S. patent that covers the method of repairing fractured bone using the aforementioned adhesive composition.

Tetranite biomaterial is the only patented bone adhesive to include phosphoserine, an organic compound, which has been shown in published literature to play a role in the process of bone regeneration.

“The granting of this patent continues to expand RevBio’s controlling intellectual property estate in the mineral-organic bone adhesive space,” said George Kay, DMD, chief scientific officer and co-founder of RevBio. This novel and very promising biomaterial distinctively combines excellent handling characteristics, weight-bearing strength, and high biocompatibility with unique adhesive and bone regenerative properties.”

“As a clinical stage company, it is exciting to receive this key patent that expands patent protection for the full spectrum of indications we are pursuing,” added Brian Hess, CEO and founder of RevBio. “This new patent will enhance the company’s core value and competitive advantage for our investors who are funding the development of this game-changing technology platform.”

Last month, the company received U.S. Food and Drug Administration (FDA) approval to expand its ongoing clinical trial to immediately fixate cranial flaps using Tetranite.